Answers are grounded in this paper and cite their sources.
Clinical features and outcomes are examined in patients with EML4-ALK, suggesting a need for targeted trials.
EML4-ALK defines a molecular subset of NSCLC with distinct clinical characteristics. Patients who harbor this mutation do not benefit from EGFR TKIs and should be directed to trials of ALK-targeted agents.
No takes yet. Share an insight, caveat, or question.
Shaw et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: